EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients

Jean J Koffi iD, Simon P Boni, Lionèle Mba, Alexandra Bitty-Anderson, Annick G Tchabert, Frank Y Toure, Patrick A Coffie, Andre Inwoley, Serge Paul Eholie, Didier K Ekouevi, Boris Tchounga

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0317223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Jean J Koffi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Programme PACCI site ANRS de Côte d'Ivoire, Abidjan, Côte d'Ivoire. Hauptthemen laut MEDLINE: HIV Infections, HIV-2. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People living with HIV-2 are mainly found in West Africa and their identification and treatment have been impaired by diagnostic challenges and availability of effective antiretroviral treatment (ART). With the roll out of first line dolutegravir (DTG)-based regimen, the situation may have improved, emphasizing the need for data on long-term treatment outcomes and advanced HIV disease among ART-experienced people living with HIV-2.

Method

A prospective cohort was initiated in 2012 in Côte d’Ivoire and Burkina Faso. All adult patients from Côte d’Ivoire with an undetectable viral load, were included and followed up. HIV-2 viral load and CD4 counts were done during the routine follow-up visits and a detailed clinical assessment was done during the last follow up visit of the year 2018 corresponding to the censor date of the cohort. Outcomes were described as follow: in care (known alive and present during the last ART follow up visit), loss to follow-up (absent for more than 90 days and not reported dead), and dead (reported dead with a date of event). Advanced HIV disease followed WHO definition and virologic failure was define as viral load > 50 copies/mm 3 . The Kaplan-Meier curve was used to estimate mortality and Loss to follow-up probability.

Results

Among the 108 HIV-2 patients in virologic success in 2012, 95 agreed to participate and were enrolled in the “success cohort”. Their median age was 53 [47–60] years and all of them were receiving boosted-lopinavir-based ART regimen. Of the 95 participants, 65 (68.4%) remained in care, 20 (21.1%) were loss to follow-up and 10 (10.5%) were reported dead. The survival analysis retrieved a decreasing probability of remaining alive and in care over the time, moving from 90% to 80.7% and to 73.0% after 24, 48 and 72 months respectively. Overall, 36 (37.9%) patients presented with advanced HIV disease at their last visit, higher among those dead/ loss to follow-up compared to those remaining in care (60.0% vs 27.7%; p-0.003).

Conclusion

High advanced HIV disease rate was found in HIV-2 patients, six years after an initial virologic success. This emphasizes the need to enable the one-stop-shop model that allow an early management of opportunistic infections while integrating non-communicable diseases services in HIV-2 care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-2HumansMaleFemaleViral LoadAdultMiddle AgedCote d'IvoireLost to Follow-UpProspective StudiesCD4 Lymphocyte CountBurkina FasoPyridonesFollow-Up StudiesAnti-HIV AgentsOxazinesTreatment OutcomePiperazinesHeterocyclic Compounds, 3-RingDolutegravir

Substanzen

PyridonesAnti-HIV AgentsOxazinesPiperazinesHeterocyclic Compounds, 3-RingDolutegravir

Autor:innen und Institutionen

  • Programme PACCI site ANRS de Côte d'Ivoire, Abidjan, Côte d'Ivoire.
  • Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte d'Ivoire.
  • Programme de lutte contre le cancer, Abidjan, Côte d'Ivoire.
  • Research and Diagnosis Center for AIDS and other infectious diseases (CeDReS), CHU (University Hospital) of Treichville, Abidjan, Côte d'Ivoire.
  • Centre Inserm 1219 & Institut de Santé Publique d'épidémiologie et de développement, Université de Bordeaux, Bordeaux, France.
  • Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire.

ORCID-Profile: Jean J Koffi

Zitieren

APA

Koffi, J. J., Boni, S. P., Mba, L., Bitty-Anderson, A., Tchabert, A. G., Toure, F. Y., Coffie, P. A., Inwoley, A., Eholie, S. P., Ekouevi, D. K., & Tchounga, B. (2025). Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0317223

Vancouver

Koffi JJ, Boni SP, Mba L, Bitty-Anderson A, Tchabert AG, Toure FY, et al. Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients. PLOS ONE. 2025. doi:10.1371/journal.pone.0317223

BibTeX
@article{Koffi2025,
  author = {Koffi, Jean J and Boni, Simon P and Mba, Lionèle and Bitty-Anderson, Alexandra and Tchabert, Annick G and Toure, Frank Y and Coffie, Patrick A and Inwoley, Andre and Eholie, Serge Paul and Ekouevi, Didier K and Tchounga, Boris},
  title = {Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0317223}
}
Kostenlos starten →